Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: A "real-world" retrospective study
Peña‐Ceballos J, Moloney PB, Munteanu T, Doyle M, Colleran N, Liggan B, Breen A, Murphy S, El‐Naggar H, Widdess‐Walsh P, et al.
Epilepsia · 2023
Key finding
Fifty-seven patients received cenobamate for at least 3 months (median duration, 11 months).
- Condition
- Chronic Fatigue Syndrome
- Stimulation
- taVNS
- Evidence tier
- Observational / Cohort
- Participants
- —
Cite this study
Peña‐Ceballos, J., Moloney, P. B., Munteanu, T., Doyle, M., Colleran, N., Liggan, B., Breen, A., Murphy, S., El‐Naggar, H., Widdess‐Walsh, P., & Delanty, N. (2023). Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: A "real-world" retrospective study. Epilepsia, 64(5), 1225-1235. https://doi.org/10.1111/epi.17549
Related studies in Chronic Fatigue Syndrome
Potential application of brain-gut axis-based treatments in Long COVID and ME/CFS: a case-based systematic review
Kim et al. · Journal of translational medicine · 2026 · Systematic Review / Meta-Analysis
Complementary and alternative medicine for long COVID: a systematic review of randomized controlled trials
Yang et al. · Therapeutic advances in chronic disease · 2023 · Systematic Review / Meta-Analysis
Evidence of bottom-up homeostatic modulation induced taVNS during emotional and Go/No-Go tasks
Camargo et al. · Experimental brain research · 2024 · Randomised Controlled Trial
The effects of non-invasive vagus nerve stimulation on fatigue in participants with primary Sjogren's syndrome
Tarn et al. · Neuromodulation · 2023 · Randomised Controlled Trial
Summary by Vagus Research. Always consult the primary source for the authoritative record.